Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019-2022
Abstract Objective: Single-center and regional studies have reported outcomes after treatment with cefiderocol, a novel siderophore cephalosporin. We report on real-world use, clinical outcomes, and microbiological outcomes with cefiderocol therapy within the Veterans' Health Administration (VH...
Saved in:
Main Authors: | Andrew Chou (Author), David Ramsey (Author), Eva Amenta (Author), Barbara W. Trautner (Author) |
---|---|
Format: | Book |
Published: |
Cambridge University Press,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world clinical outcomes of cefiderocol therapy in the Veterans Health Administration, 2019-2022
by: Eva Amenta, et al.
Published: (2023) -
Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art
by: Alessio Sollima, et al.
Published: (2024) -
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
by: Chuanhai Wang, et al.
Published: (2022) -
The solution to drug resistance of Gram-negative bacteria - Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023) -
Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
by: Frontiers Production Office
Published: (2022)